Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurocrine falls on indiplon approvable letter

NBIX fell $5 (49%) to $5.25 on Thursday after receiving a second FDA approvable letter for indiplon 5

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE